It is a type of PDE5 inhibitor that is used for the treatment of erectile dysfunction, benign prostatic hypertrophy, and pulmonary arterial hypertension. The effect of this is to relax the muscles in the blood vessels and increase the flow of blood to the corpus cavernosum. The mechanism of action is through inhibition of cGMP-specific phosphodiesterase type 5 (PDE5) activity. PDE5 degrades cGMP in the corpus cavernosum located around the penis. Thus, tadalafi leads to an increased concentration of cGMP, which further causes relaxation of smooth muscle and increased blood flow in the corpus cavernosum. Some clinical studies also implied that it could improve endothelial function in men at increased cardiovascular risk and reduce urinary tract symptoms secondary to benign prostatic hyperplasia.
CAS 171596-29-5 Product Information
|Product Name:||CAS 171596-29-5|
|Synonyms:||ICOS 351;UK 336017;(6r,12ar)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione;Cialis ,98%;Pyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-e|
|Boiling Point:||679.1±55.0 °C at 760 mmHg|
|Appearance:||White to beige Powder|
|Applications:||analgesic, norepinephrine uptake blocker, mu-opiod receptor agonist.A phosphodiesterase 5 inhibitor.It is used for the treatment of erectile dysfunction.|
|Solubility:||DMSO: soluble20mg/mL, clear|
|Storage:||Sealed in dry,2-8°C|
There are no reviews yet.